Recombinant human interleukin 2 (rIL-2) enhancement of antibody production by human-human hybridomas.
We studied the effect of highly purified recombinant interleukin 2 from Escherichia coli (rIL-2) on antibody production by our human hybridomas. Increasing concentrations of rIL-2 were directly related to increased production of immunoglobulin, which reached peak levels of 13-25 micrograms/ml, a 10- to 20-fold increase over untreated hybridomas. We were unable to demonstrate large quantities of the IL-2 receptor on the hybridomas as measured by an anti-TAC monoclonal antibody. The data suggest that the antibody enhancement phenomenon is mediated by IL-2 and that is a new, effective way to achieve higher levels of immunoglobulin from human hybridomas.
D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000917:Antibody Formation / Q000187:drug effects*; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology*; D009218:Myosins / Q000276:immunology; D011971:Receptors, Immunologic / Q000502:physiology*; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins / Q000494:pharmacology; D013297:Streptococcus pyogenes / Q000276:immunology
D000907:Antibodies, Bacterial; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D009218:Myosins